Key facts, as of
As of September 29, 2026, Thermo Fisher Scientific (TMO) trades at $679.61, up 47.1% over the past year. It is at the top of its 52-week range ($435.27 to $682.98). It sits 25.5% above its 200-day average of $541.33, the usual sign of a long-term uptrend. Its 30-day volatility is 23.6% annualized, which we rate medium risk. It has a trailing P/E of 36.6 and a dividend yield of 0.28%.
Cite: Portfolio Terminal, "Thermo Fisher Scientific (TMO) stock analysis", 2026-09-29. https://portfolio-terminal.com/analyse/tmo
Where it trades today
trading 99% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- TMO trades at 36.6x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- TMO carries a beta of 0.85, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- TMO is in a bullish short-term regime and only 0.5% below its 52-week high, so the question is whether fundamentals can keep pace with that stronger tape.
Portfolio Use Case
- TMO is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in TMO.
- If the short-term trend rolls over while volume fades, the market may stop paying up for momentum before the fundamentals change.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
Methodology
- Price, market cap, beta, yield, and liquidity fields for TMO come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for TMO. Last refresh: Sep 29, 2026, 10:32 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Thermo Fisher Scientific does
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government,…
Employees
125,000
Industry
Diagnostics & Research
Headquarters
Waltham, United States
What analysts expect
TMO carries a buy consensus from 27 analysts, with an average price target of $653.11 versus $679.61 today (-3.9%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
TMO generated $46.34B in trailing revenue (10.5% year over year), with a 15.0% net margin, and $6.24B of free cash flow, against $38.48B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $44.56B | $18.24B | $8.11B | $6.70B | $17.77 | $6.29B |
| 2024 | $42.88B | $17.70B | $7.72B | $6.33B | $16.58 | $7.27B |
| 2023 | $42.86B | $17.10B | $7.32B | $6.00B | $15.52 | $6.93B |
| 2022 | $44.91B | $18.97B | $8.51B | $6.95B | $17.75 | $6.91B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
TMO beside the healthcare names it is usually measured against.
What the chart is saying
Trading at its high for the year, with no resistance overhead.
uptrend- Price is 11.4% above its 50-day average and 25.5% above its 200-day.
- The 50-day crossed above the 200-day on 2026-08-18 (a “golden cross”).
- RSI at 74 is overbought: strong momentum, and stretched.
- Nothing above has stopped it this year; the nearest floor is $645.49 (-5.0%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is TMO a good buy right now?
Thermo Fisher Scientific trades at 36.6x earnings. This is above market average, reflecting growth expectations. Current risk level is Medium based on 23.6% volatility.
Does TMO pay dividends?
Yes, Thermo Fisher Scientific offers a dividend yield of 0.28%. That is roughly $1.90 per share a year.
How volatile is TMO?
With 30-day annualized volatility of 23.6% and beta of 0.85, TMO is classified as Medium risk. The stock tends to be more stable than the market average.
What is the analyst price target for TMO?
The average analyst price target for Thermo Fisher Scientific (TMO) is $653.11 based on 27 analyst estimates, about 3.9% below the current price of $679.61. The published range runs from $520.00 to $780.00.
How much revenue does TMO generate?
Thermo Fisher Scientific reported $46.34B in trailing twelve-month revenue. Revenue growth is running at 10.5% year over year. Net margin sits at 15.0%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare TMO with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.